Drug intelligence / Profile preview

D744

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

D744 is referenced as a code name for a drug used in clinical pharmacokinetic studies, specifically in combination with other agents such as CKD-501 and D150. The available information does not provide details on its chemical structure, mechanism of action, or therapeutic indication. It appears to be an investigational compound evaluated for pharmacokinetics and safety, possibly related to metabolic or cardiovascular conditions based on the context of associated drugs (e.g., lobeglitazone trials for type 2 diabetes). No further mechanistic or clinical data are available from the provided sources[1][2].

Beyond the preview

Go deeper on D744.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D744.

Explore the full profile